{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Injection&page=9",
    "query": {
      "intervention": "Buffered Injection",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 202,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Injection&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Buffered+Injection&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T10:36:58.465Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04347239",
      "title": "Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Leronlimab (700mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 484,
      "start_date": "2020-04-16",
      "completion_date": "2022-06-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 18,
      "location_summary": "Alexander City, Alabama • Fullerton, California • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04347239"
    },
    {
      "nct_id": "NCT04725877",
      "title": "VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV I Infection"
      ],
      "interventions": [
        {
          "name": "VIR-1111",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 27,
      "start_date": "2020-12-28",
      "completion_date": "2022-12-05",
      "has_results": false,
      "last_update_posted_date": "2023-02-27",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Seattle, Washington • Madison, Wisconsin",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04725877"
    },
    {
      "nct_id": "NCT05501327",
      "title": "Dose Regimen Study of SLI-F06 in Healthy Volunteers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Scar",
        "Wound Healing"
      ],
      "interventions": [
        {
          "name": "SLI-F06",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Scarless Laboratories, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 30,
      "start_date": "2022-07-25",
      "completion_date": "2024-10-25",
      "has_results": false,
      "last_update_posted_date": "2023-07-27",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 2,
      "location_summary": "Encinitas, California • Austin, Texas",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05501327"
    },
    {
      "nct_id": "NCT00646399",
      "title": "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcal Sepsis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pagibaximab 50 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosynexus Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "48 Hours",
        "sex": "ALL",
        "summary": "Up to 48 Hours"
      },
      "enrollment_count": 1579,
      "start_date": "2009-03",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2011-10-24",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 1,
      "location_summary": "Gaithersburg, Maryland",
      "locations": [
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646399"
    },
    {
      "nct_id": "NCT02329834",
      "title": "Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Fursemide Injection Solution for subcutaneous administration (80 mg)",
          "type": "DRUG"
        },
        {
          "name": "Furosemide Injection, USP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "scPharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2015-04",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2022-12-02",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 1,
      "location_summary": "DeLand, Florida",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02329834"
    },
    {
      "nct_id": "NCT02253147",
      "title": "TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nasolabial Folds, Wrinkles"
      ],
      "interventions": [
        {
          "name": "TEOSYAL® RHA Ultra Deep",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Teoxane SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2014-09",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-03-27",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 4,
      "location_summary": "Beverly Hills, California • Bradenton, Florida • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02253147"
    },
    {
      "nct_id": "NCT03300050",
      "title": "Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza",
        "Vaccine"
      ],
      "interventions": [
        {
          "name": "cH8/1N1 LAIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cH5/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AS03-adjuvanted cH8/1N1 IIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Normal saline",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline (PBS)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 65,
      "start_date": "2017-10-10",
      "completion_date": "2019-08-09",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03300050"
    },
    {
      "nct_id": "NCT00270218",
      "title": "Safety of and Immune Response to Two Different HIV Vaccines, Each Followed by a Adenoviral Vaccine Boost, in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVADV014-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRC-HIVDNA009-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FFB",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PBS",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 66,
      "start_date": "2006-02",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • San Francisco, California • New York, New York + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00270218"
    },
    {
      "nct_id": "NCT02277184",
      "title": "Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell of Head and Neck"
      ],
      "interventions": [
        {
          "name": "Ficlatuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Intensity Modulated Radiotherapy (IMRT)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Julie E. Bauman, MD, MPH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-09",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-11-13",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 3,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02277184"
    },
    {
      "nct_id": "NCT01765426",
      "title": "Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "TDV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 67,
      "start_date": "2013-02-15",
      "completion_date": "2014-06-26",
      "has_results": true,
      "last_update_posted_date": "2019-07-18",
      "last_synced_at": "2026-10-23T10:36:58.465Z",
      "location_count": 2,
      "location_summary": "Galveston, Texas • Seattle, Washington",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01765426"
    }
  ]
}